Robert D Jones
Radiology at Box Elder Pl, San Diego, CA
License number
Florida 55695
Effective Date
Jan 16, 2013
Expiration Date
Dec 31, 2002
Category
Health Care
Type
Radiologic Technology
Address
Address
11451 Box Elder Pl, San Diego, CA 92127
Phone
(619) 778-3599
Professional information
Robert Jones - San Diego, CA
Work:
St. Vincent De Paul Village
Volunteer C.H.U.M. Drop-in Center - Duluth, MN
Assistant Staff Personnel Y.W.C.A - Duluth, MN
Night Front Desk
Volunteer C.H.U.M. Drop-in Center - Duluth, MN
Assistant Staff Personnel Y.W.C.A - Duluth, MN
Night Front Desk
Education:
Egyptian High School - Tamms, IL
High School Diploma
High School Diploma
Robert Jones - San Diego, CA
Work:
To secure a part time position in manufacturing, production, or customer service
Education:
San Diego Mesa College - San Diego, CA
Chemical
Chemical
Robert Jones, San Diego CA
Work:
Century 21
San Diego
(858) 485-8184
San Diego
(858) 485-8184
Grp119 Receptor Agonists In Methods Of Increasing Bone Mass And Of Treating Osteoporosis And Other Conditions Characterized By Low Bone Mass, And Combination Therapy Relating Thereto
US Patent:
7816364, Oct 19, 2010
Filed:
Apr 10, 2007
Appl. No.:
11/989038
Inventors:
Zhi-Liang Chu - San Diego CA, US
James N. Leonard - San Diego CA, US
Juerg Lehmann - San Diego CA, US
Robert M. Jones - San Diego CA, US
James N. Leonard - San Diego CA, US
Juerg Lehmann - San Diego CA, US
Robert M. Jones - San Diego CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/4965
US Classification:
514256
Abstract:
The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.
1,2,3-Trisubstituted Aryl And Heteroaryl Derivatives As Modulators Of Metabolism And The Prophylaxis And Treatment Of Disorders Related Thereto Such As Diabetes And Hyperglycemia
US Patent:
8293751, Oct 23, 2012
Filed:
Jan 14, 2004
Appl. No.:
10/541657
Inventors:
Robert M. Jones - San Diego CA, US
Graeme Semple - San Diego CA, US
Beatriz Fioravanti - Tucson AZ, US
Guilherme Pereira - San Diego CA, US
Imelda Calderon - San Diego CA, US
Jane Laguerta Uy - Monrovia CA, US
Kameshwari Duvvuri - Lexington KY, US
Jin Sun Karoline Choi - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Vibha Dave - San Diego CA, US
Mihai D. Azimioara - La Jolla CA, US
Graeme Semple - San Diego CA, US
Beatriz Fioravanti - Tucson AZ, US
Guilherme Pereira - San Diego CA, US
Imelda Calderon - San Diego CA, US
Jane Laguerta Uy - Monrovia CA, US
Kameshwari Duvvuri - Lexington KY, US
Jin Sun Karoline Choi - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Vibha Dave - San Diego CA, US
Mihai D. Azimioara - La Jolla CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
C07D 239/02
US Classification:
514256, 544327
Abstract:
The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
Combination Therapy For The Treatment Of Diabetes And Conditions Related Thereto And For The Treatment Of Conditions Ameliorated By Increasing A Blood Glp-1 Level
US Patent:
7803754, Sep 28, 2010
Filed:
Nov 22, 2006
Appl. No.:
11/603417
Inventors:
Zhi-Liang Chu - San Diego CA, US
James N. Leonard - San Diego CA, US
Hussien A. Al-Shamma - Encinitas CA, US
Robert M. Jones - San Diego CA, US
James N. Leonard - San Diego CA, US
Hussien A. Al-Shamma - Encinitas CA, US
Robert M. Jones - San Diego CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 38/00, A61K 51/00
US Classification:
514 2, 530300, 424 169
Abstract:
The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
Combination Therapy For The Treatment Of Diabetes And Conditions Related Thereto And For The Treatment Of Conditions Ameliorated By Increasing A Blood Glp-1 Level
US Patent:
2010028, Nov 11, 2010
Filed:
Nov 2, 2009
Appl. No.:
12/610918
Inventors:
Zhi-Liang Chu - San Diego CA, US
James N. Leonard - San Diego CA, US
Hussien A. Al-Shamma - Encinitas CA, US
Robert M. Jones - San Diego CA, US
James N. Leonard - San Diego CA, US
Hussien A. Al-Shamma - Encinitas CA, US
Robert M. Jones - San Diego CA, US
Assignee:
ARENA PHARMACEUTICALS, INC. - San Diego CA
International Classification:
A61K 31/506, A61K 31/4985, A61P 3/10
US Classification:
514249, 514256
Abstract:
The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
Gamma-Carboxyglutamate Containing Conopeptides
US Patent:
2006017, Aug 3, 2006
Filed:
Mar 22, 2006
Appl. No.:
11/385997
Inventors:
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Craig Walker - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Robert Jones - San Diego CA, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Craig Walker - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Robert Jones - San Diego CA, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
International Classification:
A61K 38/10, C07K 7/08, C07K 14/435
US Classification:
514013000, 530326000
Abstract:
The invention relates to γ-carboxyglutamate containing conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.
Fused-Aryl And Heteroaryl Derivatives As Modulators Of Metabolism And The Prophylaxis And Treatment Of Disorders Related Thereto
US Patent:
7132426, Nov 7, 2006
Filed:
Jul 13, 2004
Appl. No.:
10/890549
Inventors:
Robert M. Jones - San Diego CA, US
Graeme Semple - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Young-Jun Shin - San Diego CA, US
Albert S. Ren - San Diego CA, US
Imelda Calderon - San Diego CA, US
Beatriz Fioravanti - Tucson AZ, US
Jin Sun Karoline Choi - San Diego CA, US
Carleton R. Sage - Cardiff-by-the-Sea CA, US
Graeme Semple - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Young-Jun Shin - San Diego CA, US
Albert S. Ren - San Diego CA, US
Imelda Calderon - San Diego CA, US
Beatriz Fioravanti - Tucson AZ, US
Jin Sun Karoline Choi - San Diego CA, US
Carleton R. Sage - Cardiff-by-the-Sea CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/519, A61K 31/407, C07D 487/02, C07D 471/12
US Classification:
5142621, 514303, 544262, 546119
Abstract:
The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
Noise Riding Threshold
US Patent:
3961274, Jun 1, 1976
Filed:
Mar 10, 1975
Appl. No.:
5/557191
Inventors:
Robert W. Jones - San Diego CA
James K. Hall - Santee CA
James K. Hall - Santee CA
Assignee:
The United States of America as represented by the Secretary of the Navy - Washington DC
International Classification:
H03B 104, H03K 508, H04B 110
US Classification:
328165
Abstract:
A network for sensing video noise power over a wide dynamic range and outting a voltage proportional to that noise power. The input signal is filtered, inverted and rectified to separate the noise component from the signal. The noise component is then converted to a negative level voltage which is added to first and second preset voltages. A non-linear output voltage which is a function of the first signal sum is provided for driving the voltage threshold devices in external equipment. A linear voltage output which is a function of the second signal sum is also provided for driving the voltage threshold devices of external equipment.